- Free from Publisher V Bril, RA Buchanan - Diabetes Care, 2004 - Am Diabetes Assoc OBJECTIVE—The primary purpose of this investigation was to determine whether
AS-3201, a new aldose reductase inhibitor, penetrates the sural nerve and
inhibits sorbitol and fructose accumulation in patients with diabetic ... Cited by 47 - Related articles - BL Direct - All 7 versions
- Free from Publisher N Hotta, T Toyota, K Matsuoka, Y Shigeta, R … - Diabetes Care, 2001 - cat.inist.fr OBJECTIVE The purpose of this study was to evaluate the efficacy of fidarestat,
a novel aldose reductase BAR) inhibitor, in a double-blind placebo controlled
study in patients with type 1 and type 2 diabetes and associated peripheral ... Cited by 62 - Related articles - BL Direct - All 5 versions
[CITATION] the Ranirestat Study Group: Long-term effects of ranirestat (AS-3201) on peripheral nerve …
V Bril, RA Buchanan - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Patients with mild to moderate DSP, as determined
by the presence of sural nerve responses, were enrolled in a double-blind,
placebo-controlled biopsy trial and randomized to placebo or 5 or 20 mg/day ... Cited by 44 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org N Hotta, Y Akanuma, R Kawamori, K Matsuoka, … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Subjects with diabetic neuropathy, median motor
nerve conduction velocity (MNCV) ≥40 m/s, and HbA 1c ≤9% were enrolled in
this open-label, multicenter study and randomized to 150 mg/day epalrestat ... Cited by 46 - Related articles - BL Direct - All 5 versions
V Bril, Y Ono, RA Buchanan - Diabetes care, 2004 - Am Diabetes Assoc OBJECTIVE—Nerve sorbitol levels have been measured in sural nerve biopsy
samples from patients with diabetic sensorimotor polyneuropathy in several
studies using different methods and measurement units. In this study, we ... Cited by 7 - Related articles - BL Direct - All 6 versions
M Kurono, I Fujiwara, K Yoshida - Biochemistry, 2001 - pubs.acs.org Aldose reductase (AR) is an NADPH-dependent enzyme implicated in diabetic
complications. AS-3201 [(R)-(−)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-
tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone] ... Cited by 18 - Related articles - BL Direct - All 4 versions
PJ Oates - Current drug targets, 2008 - ingentaconnect.com Abstract: Aldose reductase (AR) enzymatically transforms cytosolic glucose into
sorbitol, a molecule that poorly pene- trates cell membranes and is sometimes
slowly metabolized. Hyperglycemia can cause intracellular accumulation of ... Cited by 26 - Related articles - BL Direct - All 3 versions
N Hotta - Nagoya Journal of Medical Science, 1997 - ir.nul.nagoya-u.ac.jp 91 POLYOL PATHWAY AND DIABETIC COMPLICATIONS hyperglycemic conditions, there is
a considerable increase in intracellular sorbitol levels. Namely, AR has a high
capacity and a low affinity for glucose, but sorbitol dehydrogenase (SDH) ... Cited by 29 - Related articles - BL Direct - All 2 versions
M Kurono, A Fujii, M Murata, B Fujitani, T … - Biochemical pharmacology, 2006 - Elsevier AS-3201 [(3R)-2′-(4-bromo-2-fluorobenzyl)spiro[pyrrolidine-3,4′(1′H)-
pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone] is a structurally novel
and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) ... Cited by 8 - Related articles - All 4 versions
